



REGENXBIO to Participate in Upcoming Investor and Scientific Conferences

December 01, 2015 10:13 AM EST

ROCKVILLE, Md., Dec. 1, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy, today announced that President and CEO Kenneth T. Mills will participate in the following upcoming investor and scientific conferences:

27th Annual Piper Jaffray Healthcare Conference

Date: Tuesday, December 1, 2015

Location: New York Palace Hotel

Gene Therapy for Ophthalmology Panel: 10:00 – 10:55 am ET

Fireside Discussion: 12:30 – 12:55 pm ET

Genetic Rx

Date: Thursday, December 3, 2015

Location: Joseph B. Martin Conference Center at Harvard Medical School

Genetic Therapies 2015 Milestones and 2016 Goals Panel: 8:30 – 9:10 am ET

About REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing *in vivo* gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of September 30, 2015, REGENXBIO's NAV Technology Platform is being applied in the development of 23 product candidates for a variety of diseases, including five internally developed candidates and 18 partnered candidates developed by REGENXBIO's licensees.

CONTACT: Investors

Elizabeth Broder, 646-378-2945

ebroder@troutgroup.com

Media [

Laura Bagby, 312-448-8098

lbagby@6degreespr.com

[REGENXBIO](#)

REGENXBIO Inc.